Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Texas Heart Institute currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units, indicating a portfolio that spans multiple specialized examination groups. The workload involves 4 distinct examiners, showing that each action is assigned to a different individual. This distribution requires the legal team to monitor several different examination styles simultaneously.
KHADIJEH A VAHDAT is identified as the busiest examiner for this portfolio, currently handling 1 pending action. This specific workload suggests that no single examiner is overwhelmed by the institute's current filings. Practitioners should prepare for varied examination outcomes given the involvement of 3 different art units. The presence of 4 pending office actions across 4 distinct examiners means that prosecution strategies must be tailored to several different individuals. This diversity in examiners and art units suggests a need for a flexible approach to patent prosecution for the institute.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §102 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAHDAT, KHADIJEH A | 1 | 79.5% | +20.1% |
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
| SAHAND, SANA | 1 | 63.4% | +23.8% |
| BARSKY, JARED | 1 | 50.2% | +22.7% |
| ARIETI, RUTH SOPHIA | 1 | 46.7% | +71.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037029 | SUPPRESSING HIPPO SIGNALING IN THE STEM CELL NICHE PROMOTES SKELETAL MUSCLE REGENERATION | ARIETI, RUTH SOPHIA | 21d |
| 19099446 | Tool and Method for Cardiac Ablation Using Hydrogel | VAHDAT, KHADIJEH A | — |
| 18292464 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | BARSKY, JARED | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037029 | SUPPRESSING HIPPO SIGNALING IN THE STEM CELL NICHE PROMOTES SKELETAL MUSCLE REGENERATION | ARIETI, RUTH SOPHIA | 21d |
| 19099446 | Tool and Method for Cardiac Ablation Using Hydrogel | VAHDAT, KHADIJEH A | — |
| 18294893 | PHRENIC NERVE PACING DEVICE | SAHAND, SANA | — |
| 18292464 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | BARSKY, JARED | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 3796 | 1 |
| 1628 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19099446 | Tool and Method for Cardiac Ablation Using Hydrogel | VAHDAT, KHADIJEH A | — | §102§103§112 | Non-Final OA | — | Pending | Jan 28, 2025 |
| 18682681 | PIPERAZINE-BASED AGONISTS OF LFA-1 AND VLA-4 | YOO, SUN JAE | 1621 | §102 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18294893 | PHRENIC NERVE PACING DEVICE | SAHAND, SANA | 3796 | §103 | Final Rejection | — | Pending | Feb 02, 2024 |
| 18292464 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | BARSKY, JARED | 1628 | §102§103§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18037029 | SUPPRESSING HIPPO SIGNALING IN THE STEM CELL NICHE PROMOTES SKELETAL MUSCLE REGENERATION | ARIETI, RUTH SOPHIA | 1635 | §103§112Other | Final Rejection | 21d | Pending | May 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial